摘要
目的探讨间歇性内分泌联合中药治疗晚期前列腺癌(PCa)的疗效及对前列腺特异性抗原(PSA)、血管内皮生长因子(VEGF)和免疫功能的影响。方法选取2016年1月—2018年12月我院收治的106例晚期PCa患者为研究对象,按照随机数表法分为对照组(n=53)和观察组(n=53)。对照组采用间歇性内分泌治疗,观察组采用间歇性内分泌联合中药治疗。观察两组患者的临床疗效及不良反应发生情况,并比较治疗前和治疗后6个月的生活质量以及血清PSA、VEGF和免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平。结果治疗后观察组总有效率(88.7%)明显优于对照组(69.8%)(P<0.05)。治疗期间两组患者不良反应发生率(28.3%vs.22.6%)比较,差异无统计学意义(P>0.05)。治疗后两组患者性功能、泌尿功能、肠道功能及激素功能评分均明显低于治疗前(P<0.05),且观察组性功能[(85.70±4.52)vs.(79.62±4.80)]、泌尿功能[(41.85±4.10)vs.(32.40±3.72)]、肠道功能[(87.52±8.50)vs.(80.47±7.80)]及激素功能[(78.46±7.70)vs.(70.62±7.35)]评分均明显高于对照组(P<0.05)。治疗后两组患者血清PSA、VEGF水平均明显低于治疗前(P<0.05),但两组患者血清PSA[(4.30±1.25)ng·mL-1 vs.(4.72±1.38)ng·mL-1]、VEGF[(69.50±7.42)ng·mL-1 vs.(73.40±8.25)ng·mL-1]水平无明显差异(P>0.05)。治疗后两组患者CD3+、CD4+及CD4+/CD8+水平均明显高于治疗前(P<0.05),且观察组CD3+[(68.45±8.36)vs.(64.20±7.82)]、CD4+[(44.85±6.12)vs.(40.38±5.30)]及CD4+/CD8+[(1.70±0.28)vs.(1.43±0.16)]水平均明显高于对照组(P<0.05)。结论间歇性内分泌联合中药治疗晚期PCa具有较好的疗效,能提高患者免疫功能,改善生活质量,且不增加不良反应。
Objective To investigate the efficacy of intermittent endocrine therapy combined with traditional Chinese medicine in the treatment of advanced prostate cancer(PCa)and its effects on prostate-specific antigen(PSA),vascular endothelial growth factor(VEGF)and immune function of patients.Methods A total of 106 patients with advanced PCa admitted to Hainan West Central Hospital between January 2016 and December 2018 were randomly divided into control group(n=53)and observation group(n=53).The control group was treated with intermittent endocrine therapy,while the observation group was treated with intermittent endocrine combined with traditional Chinese medicine.The clinical efficacy and adverse reactions of the two groups were observed.And the quality of life,the levels of serum prostate specific antigen(PSA),vascular endothelial growth factor(VEGF)and immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+)before treatment and six months after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group(88.7%)was significantly better than that of the control group(69.8%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(28.3%vs.22.6%)(P>0.05).The scores of sexual function,urinary function,intestinal function and hormone function in both groups after treatment were significantly lower than those before treatment(P<0.05).After treatment,the scores of sexual function[(85.70±4.52)vs.(79.62±4.80)],urinary function[(41.85±4.10)vs.(32.40±3.72)],intestinal function[(87.52±8.50)vs.(80.47±7.80)]and hormone function[(78.46±7.70)vs.(70.62±7.35)]of the observation group were significantly higher than those of the control group(P<0.05).The levels of serum PSA and VEGF in the observation group and the control group after treatment were significantly lower than those before treatment(P<0.05).However,no significant differences were observed in serum PSA[(4.30±1.25)ng·mL-1 vs.(4.72±1.38)ng·mL-1]and VEGF[(69.50±7.42)ng·mL-1 vs.(73.40±8.25)ng·mL-1]levels between the observation group and the control group after treatment(P>0.05).After treatment,the levels of CD3+and CD4+,and the CD4+/CD8+of both groups were significantly higher than before treatment(P<0.05).And the levels of CD3+[(68.45±8.36)vs.(64.20±7.82)]and CD4+[(44.85±6.12)vs.(40.38±5.30)],and the CD4+/CD8+[(1.70±0.28)vs.(1.43±0.16)]in the observation group were significantly higher than those in the control group(P<0.05).Conclusion Intermittent endocrine therapy combined with traditional Chinese medicine has a good effect in the treatment of advanced PCa.It can improve the immune function and quality of life of patients,but does not increase any adverse reactions.
作者
李梅桂
黄国定
刘海剑
曾业平
陈其珠
LI Meigui;HUANG Guoding;LIU Haijian;ZENG Yeping;CHEN Qizhu(Department of Oncology Medicine,Hainan West Central Hospital,Danzhou,Hainan,571799,China)
出处
《肿瘤药学》
CAS
2021年第3期337-341,共5页
Anti-Tumor Pharmacy
基金
海南省医药卫生科研基金项目(17A202628)。
关键词
前列腺癌
间歇性内分泌治疗
中药
前列腺特异性抗原
血管内皮生长因子
免疫功能
Prostate cancer
Intermittent endocrine therapy
Traditional Chinese medicine
Prostate-specific antigen
Vascular endothelial growth factor
Immune function
